Literature DB >> 10906737

Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.

T Okegawa1, H Noda, M Kato, A Miyata, K Nutahara, E Higashihara.   

Abstract

BACKGROUND: We tested the ability of the nested reverse transcription polymerase chain reaction (RT-PCR) assay to detect signs of biochemical recurrence of prostate cancer in the lymph nodes and peripheral blood of patients with pT3N0 prostate cancer.
METHODS: Using lymph nodes and pre- and postoperative peripheral blood dissected from 30 patients with pT3N0 prostate cancer treated by radical prostatectomy, we used RT-PCR for prostate-specific membrane antigen (PSM) and serum prostate-specific antigen (PSA) to determine the presence of prostate cancer. Results of the nested RT-PCR assay were compared with pathological stages and biochemical recurrence.
RESULTS: Two of 13 patients with capsular penetration (15%), 6 of 10 patients with invasion of seminal vesicles (60%), and 3 of 7 patients with a positive surgical margin (43%) were RT-PCR-positive for PSM and/or PSA in the lymph nodes. Results of preoperative RT-PCRs of peripheral blood for PSM and for PSA significantly differed between positive and negative results of RT-PCR in lymph nodes (P < 0.001 and P < 0.001, respectively). Results of postoperative RT-PCRs of peripheral blood for PSM and for PSA also significantly different between positive and negative results of RT-PCR in lymph nodes (P = 0.011 and P = 0.001, respectively). Nine of 11 patients with positive nested RT-PCR for PSM and/or PSA in the lymph nodes (82%) experienced biochemical recurrence. Significant difference in Kaplan-Meier recurrence-free actuarial curves was noted between patients who nested positive and negative on RT-PCR in the lymph nodes, pre- and postoperative peripheral blood, biopsy and prostatectomy Gleason score, and preoperative PSA values. In multivariate analysis, biopsy and prostatectomy Gleason score (P = 0.026, P = 0.020, respectively), pre- and postoperative RT-PCR for PSM in peripheral blood (P = 0.030 and P = 0.040, respectively), and RT-PCR for PSM in lymph nodes (P = 0.035) were independent prognostic factors.
CONCLUSIONS: Nested RT-PCR assay of the lymph nodes or peripheral blood significantly predicted biochemical recurrence after surgery. It may help identify patients at risk for recurrence and progression of prostate cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906737     DOI: 10.1002/1097-0045(20000801)44:3<210::aid-pros5>3.0.co;2-u

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.

Authors:  Mohamed S Fawzy; Randa H Mohamed; Abdel-Rahman R Elfayoumi
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

2.  Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).

Authors:  Nadir Kalfazade; Ahmet M Kuskucu; Serdar Karadag; Selcuk Sahin; Bekir Aras; Kenan Midilli; Gülden Yilmaz; Ali I Tasci
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

Review 3.  Circulating tumor cells in solid cancer: tumor marker of clinical relevance?

Authors:  Loris Bertazza; Simone Mocellin; Donato Nitti
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

4.  Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy.

Authors:  N Hara; T Kasahara; T Kawasaki; V Bilim; Y Tomita; K Obara; K Takahashi
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

5.  Prostate stem cell antigen mRNA in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer.

Authors:  Yoon Seok Suh; Jae Young Joung; Sung Han Kim; Jeong Eun Kim; Moon Kyung Choi; Weon Seo Park; Sang-Jin Lee; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  Oncotarget       Date:  2018-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.